Состояния

16 состояния здоровья с доказательными исследованиями добавок

We evaluate supplements across specific hair and scalp conditions. Each condition page ranks ingredients by evidence grade, helping you find what research actually supports for your particular concern.

How We Grade Evidence

На каждой странице состояния ингредиенты добавок ранжированы по силе клинических доказательств. Вот что означает каждая оценка:

Strong Evidence

Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.

Good Evidence

At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.

Some Evidence

Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.

Very Early Research

In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.

Alopecia Areata

2% lifetime risk

Circular bald patches Exclamation point hairs Nail pitting

Андрогенетическая алопеция

50% of men by age 50, 25% of women by age 50

Receding hairline Crown thinning Widening part +1

Возрастное истончение волос

Near-universal over age 60

Gradual density reduction Finer hair texture Slower growth rate

Выпадение волос при дефиците железа

Affects up to 60% of premenopausal women with hair loss

Diffuse thinning Increased shedding Fatigue +1

Выпадение волос при дефиците питательных веществ

Common in restrictive diets and malabsorption conditions

Diffuse thinning Dry dull hair Slow growth +1

Выпадение волос при псориазе кожи головы

45-56% of psoriasis patients have scalp involvement

Thick scales Red patches Itching +1

Выпадение волос, связанное с щитовидной железой

4-10% of general population has thyroid dysfunction

Diffuse thinning Dry brittle hair Loss of outer eyebrows

Женский тип выпадения волос

40% of women by age 50

Widening central part Diffuse crown thinning Preserved frontal hairline

Послеродовое выпадение волос

Affects 40-50% of women postpartum

Excessive shedding Thinning around temples Reduced hair density

Стрессовое выпадение волос

Increasingly common; associated with telogen effluvium

Diffuse shedding Hair thinning Slower regrowth

Телогеновый эффлувиум

Second most common cause of hair loss

Diffuse thinning Excessive shedding Reduced ponytail volume

Тракционная алопеция

Common in certain hairstyle practices

Hairline recession Broken hairs Folliculitis

Chemotherapy-Induced Hair Loss

Affects 65-85% of chemotherapy patients depending on regimen

Rapid diffuse shedding Complete scalp hair loss Eyebrow and eyelash loss +1

Hormonal Hair Changes (PCOS & Menopause)

PCOS affects 6-12% of women; menopause-related thinning affects 40%+ of postmenopausal women

Diffuse thinning Changes in hair texture Hirsutism (PCOS) +1

Brittle Hair and Nails Syndrome

Affects approximately 20% of the general population

Dry, splitting hair Increased breakage Brittle, peeling nails +1

Scalp Inflammation (Folliculitis & Dermatitis)

Seborrheic dermatitis affects 3-5% of adults; scalp involvement very common

Scalp redness Itching and flaking Pustules around follicles +1

Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.